BackEvommune Overview

Evommune Accounts Payable

Evommune's accounts payable is $5M.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$5.04M
↑ 37.33% YoYΔ $1.37M vs prior year quarter

Peer trimmed avg / median

Loading

Evommune Accounts Payable History

Loading

Evommune vs. peers: Accounts Payable Comparison

Loading

Evommune Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Evommune (EVMN) FAQ

As of the most recent data (June 2026), EVMN shows a accounts payable of $5M. That compares with $3.7M in the prior-year period — up 37.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EVMN's accounts payable is now $5M (was $3.7M) — a 37.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Evommune is outperforming or lagging.

Tracking EVMN's accounts payable over time shows whether Evommune is scaling, shrinking, or reshaping that part of the business. The current reading is $5M That compares with $3.7M in the prior-year period — up 37.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Evommune's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $5M) with ownership activity and broader fundamentals.

Evommune's accounts payable is $5M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.